Physician profile
Lynne M Lyons
NPI 1780644880
$24,385.53
in general payments reported to CMS, 2019-2025
30 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,899 · 2020: $4,029 · 2021: $6,177 · 2022: $2,254 · 2023: $1,133 · 2024: $875 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.07 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $8,635.38 | 2019-2025 | Spravato |
| Allergan, INC. | $4,287.88 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $1,950.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $1,733.69 | 2019-2025 | Nuedexta, Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,062.11 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $898.85 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $737.20 | 2019-2025 | Trintellix |
| Avanir Pharmaceuticals, INC. | $630.83 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $592.25 | 2020-2025 | Caplyta |
| Johnson & Johnson Health Care Systems INC. | $585.00 | 2022 | |
| Abbvie INC. | $552.71 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $488.85 | 2019-2025 | Fanapt |
| Axsome Therapeutics, INC. | $379.05 | 2022-2025 | Auvelity, Sunosi |
| Jazz Pharmaceuticals INC. | $312.83 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $305.52 | 2019-2024 | Ingrezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $305.20 | 2022-2025 | Lybalvi, Aristada |
| Livanova USA, INC. | $185.40 | 2021-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Bausch Health US, LLC | $96.89 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $80.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $77.44 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $76.38 | 2019 | |
| Idorsia Pharmaceuticals US INC | $71.80 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $69.54 | 2019-2020 | |
| Corium, LLC | $65.09 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $63.96 | 2023-2024 | Qelbree, Qelbree |
| Shire North American Group INC | $61.90 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $44.80 | 2024-2025 | Lumryz |
| Lilly USA, LLC | $17.39 | 2025 | Zepbound |
| Alfasigma USA, INC. | $12.58 | 2020 | |
| Neuronetics, INC. | $4.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynne Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.